DERM — Journey Medical Corporation

Journey Medical (DERM) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $16 million, a 21% increase year-over-year from $13.1 million.
• Emrosi Revenue: $6.3 million, up from $2.1 million in the prior year, reflecting strong prescription growth.
• Gross Margin: 61%, down from 63.5% due to a $1.3 million noncash inventory write-down; adjusted gross margin would be approximately 69%.
• Operating Expenses: Increased by 6% year-over-year to $10.1 million, down from $10.6 million in Q1 2025.
• Net Loss: $2.2 million ($0.08 per share), improved from a net loss of $4.1 million ($0.18 per share) in Q1 2025.
• Adjusted EBITDA: Positive $600,000 ($0.02 per share), compared to a negative $900,000 in Q1 2025.
• Cash Position: Increased to $27.2 million from $24.1 million at year-end 2025.

2. Strategic Updates and Business Highlights

• Emrosi's prescription volume grew to approximately 30,000 in Q1, up from 27,000 in Q4 2025, with a refill-to-new prescription ratio improving to 1.5:1.
• Journey Medical has secured agreements with all three major PBM-led group purchasing organizations, covering approximately 85% of commercial lives in the U.S.
• The company plans to add up to five new sales professionals to enhance commercial efforts and support the launch of up to two new niche dermatology products later in the year.
• Emrosi is gaining recognition as a standard treatment for rosacea, supported by positive clinical trial results and growing prescriber engagement.

3. Forward Guidance and Outlook

• Management is optimistic about achieving positive adjusted EBITDA for the remainder of 2026 and expects to see continued revenue growth driven by Emrosi.
• The company anticipates improved reimbursement dynamics and formulary access for Emrosi, which should enhance profitability as coverage quality improves.
• While specific financial guidance will be provided later in the year, management expects to exceed 2025 revenue levels, with a focus on sustainable profitability.

4. Bad News, Challenges, or Points of Concern

• Gross margin decline due to a noncash charge raises concerns about cost management and product profitability.
• The company faces ongoing challenges related to securing quality insurance coverage, including tier positioning and prior authorization requirements, which could impact prescription growth.
• Competitive pressures from established treatments like Oracea remain, necessitating continued focus on Emrosi’s differentiation and market positioning.

5. Notable Q&A Insights

• Management acknowledged the importance of both the quantity and quality of coverage for Emrosi, with ongoing discussions with major health plans expected to yield positive outcomes in the future.
• There is an expectation of continued growth in both prescription volume and average selling price (ASP) as reimbursement dynamics improve.
• The company is strategically balancing its focus on Emrosi while preparing to launch additional products without detracting from Emrosi's growth trajectory.
• Seasonality effects on prescription volumes are noted, but management believes the overall efficacy and patient satisfaction with Emrosi will mitigate significant seasonal declines.

Overall, Journey Medical is positioned for growth in 2026, driven by Emrosi's strong market performance and strategic initiatives, despite facing challenges in gross margin and insurance coverage dynamics.